Literature DB >> 30210991

The Changing Paradigm for the Surgical Treatment of Large Vestibular Schwannomas.

Roy Thomas Daniel1,2, Constantin Tuleasca1,2,3,4, Alda Rocca1, Mercy George2,5, Etienne Pralong1,2, Luis Schiappacasse2,6, Michele Zeverino2,7, Raphael Maire2,5, Mahmoud Messerer1,2, Marc Levivier1,2.   

Abstract

Objective  Planned subtotal resection followed by Gamma Knife surgery (GKS) in patients with large vestibular schwannoma (VS) has emerged during the past decade, with the aim of a better functional outcome for facial and cochlear function. Methods  We prospectively collected patient data, surgical, and dosimetric parameters of a consecutive series of patients treated by this method at Lausanne University Hospital during the past 8 years. Results  A consecutive series of 47 patients were treated between July 2010 and January 2018. The mean follow-up after surgery was 37.5 months (median: 36, range: 0.5-96). Mean presurgical tumor volume was 11.8 mL (1.47-34.9). Postoperative status showed normal facial nerve function (House-Brackmann I) in all patients. In a subgroup of 28 patients, with serviceable hearing before surgery and in which cochlear nerve preservation was attempted at surgery, 26 (92.8%) retained serviceable hearing. Nineteen had good or excellent hearing (Gardner-Robertson class 1) before surgery, and 16 (84.2%) retained it after surgery. Mean duration between surgery and GKS was 6 months (median: 5, range: 3-13.9). Mean residual volume as compared with the preoperative one at GKS was 31%. Mean marginal dose was 12 Gy (11-12). Mean follow-up after GKS was 34.4 months (6-84). Conclusion  Our data show excellent results in large VS management with a combined approach of microsurgical subtotal resection and GKS on the residual tumor, with regard to the functional outcome and tumor control. Longer term follow-up is necessary to fully evaluate this approach, especially regarding tumor control.

Entities:  

Keywords:  Gamma Knife; combined approach; radiosurgery; surgery; vestibular schwannoma

Year:  2018        PMID: 30210991      PMCID: PMC6133697          DOI: 10.1055/s-0038-1668540

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  59 in total

1.  Management of large vestibular schwannoma. Part I. Planned subtotal resection followed by Gamma Knife surgery: radiological and clinical aspects.

Authors:  Rick van de Langenberg; Patrick E J Hanssens; Jacobus J van Overbeeke; Jeroen B Verheul; Patty J Nelemans; Bert-Jan de Bondt; Robert J Stokroos
Journal:  J Neurosurg       Date:  2011-08-12       Impact factor: 5.115

2.  How to distinguish tumor growth from transient expansion of vestibular schwannomas following Gamma Knife radiosurgery.

Authors:  Thomas Mindermann; Ines Schlegel
Journal:  Acta Neurochir (Wien)       Date:  2014-03-30       Impact factor: 2.216

3.  [Preservation of hearing in acoustic surgery].

Authors:  G Fischer; C Fischer
Journal:  Bull Mem Acad R Med Belg       Date:  1995

4.  Outpatient gamma knife surgery for vestibular schwannoma: definition of the therapeutic profile based on a 10-year experience.

Authors:  Berndt Wowra; Alexander Muacevic; Anja Jess-Hempen; John-Martin Hempel; Stefanie Müller-Schunk; Jörg-Christian Tonn
Journal:  J Neurosurg       Date:  2005-01       Impact factor: 5.115

5.  Increased preservation of functional hearing after gamma knife surgery for vestibular schwannoma.

Authors:  Albertus T C J van Eck; Gerhard A Horstmann
Journal:  J Neurosurg       Date:  2005-01       Impact factor: 5.115

6.  Functional outcome after complete surgical removal of giant vestibular schwannomas.

Authors:  Madjid Samii; Venelin M Gerganov; Amir Samii
Journal:  J Neurosurg       Date:  2010-04       Impact factor: 5.115

7.  Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas.

Authors:  Jean Régis; William Pellet; Christine Delsanti; Henry Dufour; Pierre Hughes Roche; Jean Marc Thomassin; Michel Zanaret; Jean Claude Peragut
Journal:  J Neurosurg       Date:  2002-11       Impact factor: 5.115

8.  Treatment of large and giant residual and recurrent vestibular schwannomas.

Authors:  Ricardo Ramina; Maurício Coelho Neto; Kelly Cristina Bordignon; Tobias Mattei; Rogério Clemente; Paulo Henrique Pires Aguiar
Journal:  Skull Base       Date:  2007-03

9.  Hearing preservation in patients with unilateral vestibular schwannoma after gamma knife surgery.

Authors:  Jean Régis; Manabu Tamura; Christine Delsanti; Pierre-Hugues Roche; William Pellet; Jean-Marc Thomassin
Journal:  Prog Neurol Surg       Date:  2008

10.  Hearing preservation in surgery for large vestibular schwannomas.

Authors:  Masahiko Wanibuchi; Takanori Fukushima; John T McElveen; Allan H Friedman
Journal:  J Neurosurg       Date:  2009-10       Impact factor: 5.115

View more
  4 in total

1.  Large and small vestibular schwannomas: same, yet different tumors.

Authors:  Satoshi Kiyofuji; Brian A Neff; Matthew L Carlson; Colin L W Driscoll; Michael J Link
Journal:  Acta Neurochir (Wien)       Date:  2021-01-20       Impact factor: 2.216

2.  Subtotal Resection Followed by Adjuvant Radiosurgery for Large Vestibular Schwannomas: Outcomes with Regard to the Timing and Regimen of Irradiation.

Authors:  Hesham Radwan; Tarek Elserry; Mark B Eisenberg; Jonathan P S Knisely; Maged M Ghaly; Michael Schulder
Journal:  Acta Neurochir Suppl       Date:  2021

3.  Hearing Outcome After Linear Accelerator-Based Radiotherapy for Vestibular Schwannomas: A Retrospective Analysis of a Single Center.

Authors:  Dominique Valérie Clarence de Jel; Ernst J Smid; Tristan P C van Doormaal; Hans G X M Thomeer
Journal:  J Int Adv Otol       Date:  2021-09       Impact factor: 1.017

4.  Facial nerve function and hearing after microsurgical removal of sporadic vestibular schwannomas in a population-based cohort.

Authors:  Ismail Taha; Antti Hyvärinen; Antti Ranta; Olli-Pekka Kämäräinen; Jukka Huttunen; Esa Mervaala; Heikki Löppönen; Tuomas Rauramaa; Antti Ronkainen; Juha E Jääskeläinen; Arto Immonen; Nils Danner
Journal:  Acta Neurochir (Wien)       Date:  2019-09-07       Impact factor: 2.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.